Experimental Liver-Growing Therapy Enters Phase II Trial

LyGenesis's innovative treatment could revolutionize the way end-stage liver disease is managed by growing new livers inside patients' lymph nodes.

LyGenesis has begun a phase II trial of its experimental therapy LYG-LIV-001, aiming to grow functional ectopic livers inside a person's lymph nodes to treat end-stage liver disease (ESLD).
The therapy uses hepatocytes from donated livers, which are transplanted into the recipient's lymph nodes, where they are expected to mature into functional liver tissue.
This innovative approach could potentially save many lives by providing an alternative to traditional liver transplants, which are limited by organ availability.
The phase II trial, which has just dosed its first ESLD patient, is set to enroll a total of 12 patients and is not expected to be completed until early 2026.
LyGenesis is also developing its bioreactor technology to potentially grow other organs, including kidneys, thymus, and pancreas.